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Abstract 18 
Introduction: Existing HIV therapy using oral antiretrovirals (ARVs) can result in pill fatigue 19 
and sub-optimal adherence. Microneedle array patches (MAPs) offer non-invasive, blood-free 20 
and painless drug delivery, and may improve patient adherence. The objective of this study 21 
was to develop a novel physiologically-based pharmacokinetic (PBPK) model to simulate the 22 
systemic pharmacokinetics of cabotegravir and rilpivirine MAPs using the intradermal route. 23 
Methods: The developed PBPK models were qualified against observed pharmacokinetic data 24 
after intramuscular (IM) and intradermal administration of long-acting nanoformulated rilpi-25 
virine to rats, and for IM administration of both drugs to healthy adults. Qualified models were 26 
then utilised to estimate suitable MAP characteristics (e.g. nanoformulation dose and release 27 
rates) and inform dosing strategies to maintain plasma concentrations above target trough con-28 
centrations for the designated dosing interval. 29 
Results: PBPK models simulated q4-weekly loading and maintenance doses of 360 mg and 30 
180 mg for long-acting formulated cabotegravir between the release rates of 1×10-3 – 3×10-3 h-31 
1 and 1×10-3 – 1.5×10-3 h-1 respectively, for a 70 kg adult. Estimated patch size was 60 cm2 for 32 
a 360 mg dose of cabotegravir. For q4-weekly dosing, rilpivirine required a 1080 mg loading 33 
dose and a 540 mg maintenance dose with release rates of 1.5×10-3 – 2.5×10-3 h-1 and 5×10-4 – 34 
1×10-3 h-1, respectively. Weekly dosing was also evaluated to assess the potential application 35 
from a smaller patch size. The ability to self-administer via a patch that is only left in place for 36 
a short duration makes longer durations less important than for some other long-acting ap-37 
proaches. Weekly cabotegravir required 60 mg between release rates 7×10-3 – 9×10-3 h-1 and 38 
rilpivirine required 270 mg and 180 mg respectively between release rates of 7×10-3 – 9×10-3 39 
h-1.  40 
Discussion: This model estimated optimal dose and release rates for cabotegravir and rilpi-41 
virine MAPs. Our approach provides a computational platform to support rational develop-42 
ment of intradermal administration strategies to tackle problems associated with chronic oral 43 
ARV administration.   44 
Introduction 45 
Antiretrovirals (ARVs) have improved the average lifespan of infected individuals and also 46 
found clinical application in HIV pre-exposure prophylaxis (PrEP), preventing transmission to 47 
high risk individuals. The majority of existing ARVs are available only as oral formulations. 48 
They require daily administration and chronic dosing, often resulting in sub-optimal adherence 49 
and pill fatigue (1, 2). Alternative dosing strategies such as long-acting injectables (LAIs) have 50 
been utilised for the administration of antipsychotics (e.g. paliperidone palmitate) and contra-51 
ceptives (e.g. medroxyprogesterone), effectively addressing adherence issues associated with 52 
chronic oral administration (3). The recent development of cabotegravir and rilpivirine LAI 53 
intramuscular (IM) nanoformulations has stimulated interest in this strategy (4). 54 
The existing injectable ARV formulations face challenges that may hinder development, ac-55 
ceptability, and widespread implementation although they have proven very successful for 56 
other indications. Administration of IM injections typically requires a skilled healthcare 57 
worker. For LAI rilpivirine, two large volume injections are necessary and the formulation 58 
requires a cold-chain, thus hindering clinical implementation (5). Importantly, cold chain is 59 
required because of stability of an excipient rather than the drug itself and thus this may not be 60 
a widespread problem for the approach. Nonetheless, the need for cold chain increases cost 61 
and, in low income countries, may reduce or even prevent access to treatments. In addition, 62 
some studies noted that 20% of people administered with IM injection reportedly suffer from 63 
needle phobia. This may reduce the number of patients accepting injectables, as seen for vac-64 
cines and routine dental procedures (6). It should be noted that all existing HIV patient attitude 65 
surveys for LAI approaches have shown a high level of enthusiasm for the approach, but com-66 
plimentary approaches warrant further investigation (7-9). 67 
Microneedle array patches (MAPs) can be used for minimally-invasive intradermal delivery of 68 
micro- or nanoformulated drug into the skin (10). The intradermal route of administration has 69 
multiple advantages compared to oral intake, avoiding gastrointestinal degradation and first-70 
pass metabolism, resulting in reduced total dose and may improve patient adherence (11). 71 
MAPs disrupt the stratum corneum, the major skin barrier to drug delivery, and can deliver 72 
drugs painlessly and without drawing blood into the upper skin layers (12), thus avoiding local 73 
pain, bruising, discomfort or bleeding (13). Drugs deposited in particulate form by MAPs in 74 
viable skin layers can be absorbed systemically by the rich dermal microcirculation upon re-75 
lease into the interstitial fluid (13). Hence, MAPs represent a promising strategy for chronic 76 
administration as long as the doses necessary for adequate pharmacokinetic exposure can be 77 
achieved, and may be compatible with nanoformulation strategies being investigated for long-78 
acting drug delivery (14, 15). 79 
Various types of MAPs exist for intradermal drug delivery (e.g. hollow, dissolvable and solid) 80 
and these have been extensively studied in the delivery of various drugs, including large mol-81 
ecules and vaccines. Hollow stainless steel microneedles (AdminPen® template) have been 82 
used to deliver liquid formulations (16). MAPs can be used for the delivery of biomacromole-83 
cules (17), transcutaneous immunization (18) and hormones (19). 84 
Polymeric MAPs are suitable for LA systemic delivery of small molecules. Hydrogel-forming 85 
MAPs control drug release through in-skin hydrogel swelling (20). Micro- or nanoformulations 86 
loaded into dissolving MAPs deliver the formulations to the viable skin layers upon dissolution 87 
of the needles. Subsequent controlled drug release from the polymeric micro- or nanoparticles 88 
can then achieve LA release for sustained time intervals (21, 22). Unlike hydrogel-forming 89 
MAPs, drug release is therefore possible for weeks or even months after removal of the patch, 90 
thus potentially improving patient compliance. 91 
Preclinical and clinical evaluation of novel formulations and modes of delivery is hindered by 92 
numerous challenges. Computational simulations can support design of successful administra-93 
tion strategies and rational optimisation. Physiologically-based pharmacokinetic (PBPK) mod-94 
elling is based on the mathematical description of anatomical, physiological and molecular 95 
processes describing pharmacokinetics through the integration of drug and patient specific data 96 
(23). PBPK modelling has been increasingly used in new chemical entity (NCE) applications 97 
and in investigation of clinical scenarios, suggesting reliability in pharmacokinetic predictions. 98 
PBPK models have been used to inform drug-drug interactions, CYP induction/ inhibition, 99 
pharmacogenetics and therapy optimisation in special patient populations (24). 100 
The aim of this paper was to develop a novel intradermal PBPK model for ARV administration 101 
using MAPs. The developed model was used to identify minimum dose and a range of release 102 
rates for the LA administration of cabotegravir and rilpivirine nanoformulations to maintain 103 
plasma concentrations above established antiretroviral targets throughout dosing intervals of 104 
one to four weeks.      105 
Methods 106 
A whole-body PBPK model was used to assess the intradermal release from MAPs in healthy 107 
adults. An intradermal compartment was appended to an earlier PBPK model using Simbiol-108 
ogy® v.4.3.1., a product of MATLAB® v.8.2 (MathWorks, Natick, MA, USA 2013) (25) Drug 109 
distribution was described using blood flow-limited, first-order kinetics (26). Instant and uni-110 
form drug distribution across each tissue and organ was assumed. Ethical approval was not 111 
required for this study as the data was computer generated. 112 
Microneedle patch 113 
In this exploratory study, we used a single dissolving MAP design as a starting point, based on 114 
some of our previous work (27). The thickness of stratum corneum, viable epidermis and der-115 
mis were in the range of  12-20 µm (28), 50-80 µm (29) and 300-4000 µm (30) respectively. 116 
An 11 × 11 array of microneedles 600 µm long with an interspacing of 300 µm on a 0.49 cm2 117 
baseplate were considered as the base of a single microneedle array (27). A mean penetration 118 
depth of the microneedles after skin application was assumed to be 430 ± 6.0 µm, with a pore 119 
width of 224 ± 5.0 µm made during penetration for each microneedle (27). A maximum of 32.7 120 
mg formulation (including drug and excipients) was assumed per MAP (made up of 16.33 121 
individual microneedle arrays), with an area of 8 cm2. An average of 3.55 ml/min/100g tissue 122 
(2.8-4.3 ml/min/100g tissue) (31) and 8 x 10-6 cm3/s/cm3 of tissue (31) in the adult forearm 123 
were considered as the respective blood and lymphatic flow rates to the intradermal compart-124 
ment. 125 
Intradermal PBPK model 126 
The intradermal compartment was adapted and modified from Gajewska et al. (32), as shown 127 
in Figure 1. The intradermal compartment has been divided into four sub-compartments, 128 
namely stratum corneum, viable epidermis, hair follicles and dermis. The inserted microneedle 129 
was divided into three different compartments having a relative proportion of the total drug 130 
amount depending on insertion length and pore width of each skin layer as shown in Figure 2.  131 
The following assumptions were made in the skin compartment: 1) unidirectional drug flow 132 
from the top layer (stratum corneum) to blood circulation; 2) hair follicles cover 0.1 % of the 133 
total skin (as previously described, it was assumed that hair follicles have access to one-third 134 
of the drug traversing laterally, with one-fourth of the fine skin’s blood-flow reaching the hair 135 
follicles (32)); 3) diffusion and partition coefficients across different skin layers and nanopar-136 
ticle release rate were kept constant throughout the kinetic process; 4) only the free drug re-137 
leased from the nanoparticles diffuse through the layers of skin to reach blood circulation. Drug 138 
flow through the intradermal compartment is shown in Figure 2. The equations used in the 139 
intradermal compartment are as follows: 140 
Drug present at the microneedle depot in the stratum corneum: 141 
𝑑𝐷𝑆𝐶
𝑑𝑡
= −2 × 𝐾𝑇𝐷 ∙ 𝐷𝑆𝐶  142 
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Where DSC – total drug present at the microneedle depot in the stratum corneum, KTD – drug 144 
release rate from the encapsulated formulation, DSCD – total free drug present at the micronee-145 
dle depot in the stratum corneum at time t, KSC – permeability rate constant to the stratum 146 
corneum  147 
Drug present at the microneedle depot in the viable epidermis: 148 
𝑑𝐷𝑉𝐸
𝑑𝑡
= 𝐾𝑇𝐷 ∙ 𝐷𝑆𝐶 − 2 × 𝐾𝑇𝐷 ∙ 𝐷𝑉𝐸 149 
𝑑𝐷𝑉𝐸
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2
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Where DVE is the total drug present at the microneedle depot in the viable epidermis at time t, 151 
DVED – total free drug present at the microneedle depot in the viable epidermis at time t, PCS/W 152 
– partition coefficient between skin and water, KVE – permeability rate constant to the viable 153 
epidermis, KS – permeability rate constant to the skin/hair follicles. 154 
Drug present at the microneedle depot in the dermis: 155 
𝑑𝐷𝐷𝐸
𝑑𝑡
= 𝐾𝑇𝐷 ∙ 𝐷𝑉𝐸 + 𝐾𝑇𝐷 ∙ 𝐷𝑉𝐸𝐷 − 𝐾𝑇𝐷 ∙ 𝐷𝐷𝐸 156 
Where DDE is the total drug amount present at the microneedle depot in the dermis at time t. 157 
Drug permeation from the microneedle to the adjacent skin layers (33) is given by: 158 
−
𝑑𝑀
𝑑𝑡
= 𝐴 ∙ 𝑃𝑒 ∙ 𝐶𝑏  159 
Where M is the amount of drug permeating across the skin, A is the surface area of drug in 160 
contact with the skin, Pe is the effective permeability and Cb is the drug concentration at the 161 
depot site. 162 
Drug traversing through the stratum corneum: 163 
𝑑𝐴𝑆𝐶
𝑑𝑡
=
2
3
∙ 𝐷𝑆𝐶𝐷 ∙ 𝐾𝑆𝐶  − 𝑃𝐶𝑆𝐶/𝑉𝐸 ∙ 𝐴𝑆𝐶  164 
Where ASC is the amount present in the stratum corneum at time t, PCSC/VE – partition coeffi-165 
cient between stratum corneum and viable epidermis. 166 
Drug traversing through the viable epidermis: 167 
𝑑𝐴𝑉𝐸
𝑑𝑡
=
2
3
∙ 𝐷𝑉𝐸𝐷 ∙ 𝐾𝑉𝐸  + 𝐾𝑆𝐶/𝑉𝐸 ∙ 𝐴𝑆𝐶 − 𝐴𝑉𝐸/𝑃𝐶𝑆/𝑊 168 
Where AVE is the amount present in the viable epidermis at time t, DVED – total free drug present 169 
at the microneedle depot in the viable epidermis at time t, PCS/W – partition coefficient between 170 
skin and water. 171 
Drug traversing through the hair follicles: 172 
𝑑𝐴𝐻𝐹
𝑑𝑡
=
1
3
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1
3
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Where AHF is the amount present in the hair follicles at time t 174 
Lateral diffusion from the microneedle depot was based on the drug permeability rate and the 175 
diffusion across the skin was dependent on the drug partition coefficient between the layers. 176 
Permeability rate constants – KS, KSC, KVE and drug partition coefficients - PCSC/VE, PCS/W 177 
were derived using quantitative structure-property relationships (QSPR) informed by a previ-178 
ous publication (32) (included in the supplementary document). A summary of the various 179 
QSPR equations used for parameter computation is provided in the supplementary section. An 180 
average value was considered from the numerous equations. 181 
Human physiological parameters 182 
Key characteristics of both male and female (50:50) adults such as age ranging between 18 and 183 
60 years, weight and body mass index (BMI) were defined initially, and other key characteris-184 
tics such as body surface area (BSA) and height were computed using allometric equations. 185 
Organ weights,  volumes, and blood flow rates were computed using anthropometric equations 186 
from the literature (34, 35). The drug distribution across tissues and organs were described 187 
using first-order differential equations (36, 37). Physicochemical and drug specific properties 188 
are presented in Table 1. 189 
 
Model qualification 190 
The model was initially qualified in vivo for IM nanoformulated rilpivirine in rats followed by 191 
human data as shown in supplementary figure 1. The drug specific parameters of rilpivirine 192 
utilised in the PBPK model were qualified against available IM pharmacokinetic data followed 193 
by the qualification of the intradermal compartmental model using available in vivo data in rats 194 
from an earlier pharmacokinetic study (38). A single IM injection with two different doses - 5 195 
mg/kg and 20 mg/kg and new in vivo experiments performed in rats with a 120 mg intradermal 196 
microneedle patch administered for 8 weeks were used for model qualification. For the intra-197 
dermal patch, only 57.45% of the total available drug was assumed to be effectively delivered 198 
over the dosing interval, i.e., the total amount of drug present in the microneedles excluding 199 
the drug present in the baseplates, as determined in previous in vivo experiments (27). PBPK 200 
models were considered as qualified if the mean simulated Cmax (maximum plasma concentra-201 
tion), Ctrough (trough plasma concentration) and AUC (area under the curve) were within 50% 202 
of the mean reported in vivo data. Subsequently, the intradermal compartment was appended 203 
to a previously qualified rilpivirine PBPK model in humans (23) for pharmacokinetic predic-204 
tions.  205 
PBPK analysis 206 
PBPK predictions were performed initially for a daily oral dosing for four weeks (10 mg and 207 
25 mg once daily for cabotegravir and rilpivirine, respectively) to reach steady-state concen-208 
trations, followed by a q4-weekly loading dose with a single microneedle patch and then 11 209 
consecutive q4-weekly maintenance patches, for a total of 336 consecutive days of drug expo-210 
sure. Pharmacokinetics were predicted for various combinations of dose (180 mg, 360 mg, 540 211 
mg, 720 mg, 900 mg and 1080 mg) and release rates (5×10-4, 1×10-3, 1.5×10-3, 2×10-3, 2.5×10-212 
3 and 3×10-3 h-1) for both cabotegravir and rilpivirine. Considering smaller patch sizes, q-213 
weekly MAP doses were also modelled using loading doses – 30mg, 60 mg , 90 mg, 180 mg, 214 
 
270 mg and 360 mg --  and maintenance doses – 30mg, 60mg, 90 mg, 180 mg and 270 mg -- 215 
at various release rates (7×10-3, 8×10-3, 9×10-3, 10×10-3, 11×10-3 and 12×10-3 h-1) after achiev-216 
ing steady state concentrations from oral administration. The optimal dose and release rate were 217 
identified by implementing trial and error approach by assessing various combinations of doses 218 
and release rates. Minimum doses and a range of suitable release rates of nanoformulations 219 
were estimated such that plasma concentrations remained above minimally effective concen-220 
trations throughout the dosing interval – 1.2 mg/L for a 10 mg daily oral Ctrough for cabotegravir 221 
(39), and 70 ng/ml for a 25 mg daily oral Ctrough for rilpivirine (39).  222 
The effect of varying penetration depth was assessed at a constant pore width of 224 ± 5.0 µm 223 
and varying pore radius. The effect of pore size on the release rate pharmacokinetics of rilpi-224 
virine was also assessed at a constant microneedle length of 430 ± 6.0 µm and varying pore 225 
width at a constant dose of 720 mg and release rate of 1.5×10-3 h-1.  226 
 
Results 227 
PBPK qualification 228 
Comparisons of observed and simulated pharmacokinetic parameters at the end of eight weeks 229 
are shown in Table 2. The percentage difference of the simulated Cmax and AUC against in vivo 230 
data is less than 50% for model qualification. Simulated pharmacokinetics from the designed 231 
intradermal PBPK model also satisfied the qualification limit against experimental data. Qual-232 
ification of IM cabotegravir and rilpivirine human PBPK models is presented in the supple-233 
mentary section. 234 
Intradermal dose and release rates 235 
The Ctrough of cabotegravir and rilpivirine at various q4-weekly doses and release rates (Figure 236 
3) and weekly intradermal loading and maintenance dose and release rates (Figure 4) are 237 
shown. Our calculations indicate that a minimum q4-weekly loading dose of 360 mg with a 238 
release rate between 1×10-3 – 3×10-3 h-1, and a maintenance dose of 180 mg with a release rate 239 
of 1×10-3 –1.5×10-3 h-1 would be required for an intradermal cabotegravir MAP to maintain 240 
plasma concentrations above a target Ctrough of 1.2 µg/ml. 241 
For rilpivirine, a q4-weekly regimen requires a 1080 mg loading dose with release rates of 242 
1.5×10-3 – 2.5×10-3 h-1, and a maintenance dose of 540 mg release rates of 5×10-4 – 1×10-3 h-1 243 
to maintain a target Ctrough of 70 ng/ml.  244 
Cabotegravir q-weekly MAP administration requires a minimum loading and maintenance 245 
dose of 60 mg between the release rates of 7×10-3 and 12×10-3 h-1. But if the loading dose is 246 
increased to 90 mg, a maintenance dose of 30 mg would be enough to have plasma concentra-247 
tions over the target Ctrough. For rilpivirine a loading dose of 270 mg and a maintenance dose 248 
 
of 180 mg, with a nanoformulation release rate ranging from 7×10-3 – 9×10-3 h-1. This is sig-249 
nificantly higher than the optimal release rate observed for q4-weekly formulations. However, 250 
if the loading dose is increased to 360 mg, the required maintenance dose falls to 90 mg to 251 
sustain the required Ctrough. 252 
 
Effect of needle length, pore radius and release rate 253 
The effect on pharmacokinetics of rilpivirine for varying penetration depths and needle pore 254 
sizes at a constant dose and release rate are shown in Figure 5a & b. The pharmacokinetic 255 
parameters Cmax and AUC increased as the penetration depth increased. However, there was 256 
no significant difference in the simulated Ctrough. Neither a significant difference nor a trend 257 
was observed in the pharmacokinetic parameters as the pore radius increased (Figure 5b).  258 
Simulated intradermal administration of rilpivirine predicted a rise in Cmax as the release rate 259 
increased. However, Ctrough increased until a release rate of 1.5×10
-3 h-1 and faster release rates 260 
were characterised by decreasing Ctrough (Figure 6a). At a constant release rate, as the dose 261 
increased, rilpivirine pharmacokinetics increased accordingly (6b).  262 
 
Discussion 263 
Non-invasive intradermal MAPs may represent effective novel drug delivery vehicles for 264 
chronic administration of ARVs. In this study, a compartmental PBPK model was designed 265 
and integrated with a previously published whole-body PBPK model (25). This was first qual-266 
ified with observed data in rats and humans followed by informing nanoformulation character-267 
istics in humans for cabotegravir and rilpivirine MAPs.  268 
Model qualification against observed data showed satisfactory results with differences less than 269 
50% in line with convention for this approach. Subsequently, the models were utilised to sim-270 
ulate administration of rilpivirine and cabotegravir LA formulations using MAPs. A range of 271 
release rates were evaluated to identify the optimal dosing values that would sustain plasma 272 
concentrations over established targets throughout the dosing interval at the lowest possible 273 
doses.  274 
The simulations of cabotegravir MAPs indicate an initial minimum monthly dose of 360 mg 275 
and a maintenance dose of 180 mg. Consequently, a MAP with high drug loading will be re-276 
quired. In the past, several examples of MAPs containing drug loading between 50 and 90% 277 
have been reported (40, 41). Additionally, in order to maximize drug loading in the needle tips, 278 
differently shaped MAPs may be used. Patches containing a higher needle density (19×19) 279 
while keeping the needle geometry (600 µm height and 300 µm base diameter) have been pre-280 
viously used (42-45). These MAPs showed similar insertion depths as the 11×11 MAPs (ap-281 
proximately 450 µm using manual insertion) (45) but have three times more needles in the 282 
same MAP area. Therefore, with drug loading of 50% to 90%, the density of common poly-283 
meric materials used to prepare MAPs (1.2 g/cm3) (46), and the volume of the needles tips, all 284 
the drug present in the needles can be successfully delivered (40, 41). The estimated patch size 285 
for the loading dose of cabotegravir will range between 70 and 90 cm2 (based on a loading of 286 
 
32.7 mg of formulation per 8 cm2). On the other hand, the maintenance dose patch will have a 287 
size ranging from 35 to 45 cm2. Although the required patch sizes seem large, smaller patches 288 
can be achieved with higher drug loading and since these are dissolvable patches, they can be 289 
removed within a short span of time (<24 h) subsequent to their application.  290 
Following a similar rationale, rilpivirine could be formulated in q-weekly patches (weekly 291 
loading and maintenance doses of 270 mg and 180 mg, respectively). Our model suggests that 292 
the doses required for q4-weekly patches of RPV will require unrealistically large patches be-293 
tween 130 – 260 cm2. If a 19×19 RPV MAP can be prepared, the patch sizes will range between 294 
25 and 44 cm2 for the q-weekly RPV loading dose and between 15 and 30 cm2 for the mainte-295 
nance dose. High variability in dose predictions were observed due to the high variation in the 296 
abundance of cytochrome P450 enzyme across the population that affects the systemic clear-297 
ance of rilpivirine.  298 
The presented data indicate that a weekly combination CAB and RPV may be achievable for a 299 
self-administered therapy. These patch sizes seem large, but it is important to note that con-300 
ventional transdermal patches with sizes up to 140 cm2 can be found in the market for post-301 
herpetic neuralgia (47). Moreover, it has been reported that manual application of larger MAPs 302 
has been carried out successfully in human volunteers (11). However, the patient must be 303 
properly instructed as to how these patches should be applied (11). It should also be noted that 304 
the required patch size could be reduced by using more potent ARV formulations, or higher 305 
drug loading. 306 
The parametrisation of drug partition coefficients and permeability rates between skin tissues 307 
were based on previous models, and when multiple parameters were available, an average value 308 
was selected (correlations shown in the supplementary document). However, standardised ex-309 
 
perimental methodology for the characterisation of these parameters and in vitro - in vivo ex-310 
trapolation would support a more reliable parametrisation with application across different 311 
computational models.  312 
Several percutaneous in silico models have been published to describe drug absorption kinetics 313 
for topical or systemic delivery. Some relevant examples include a percutaneous model for 314 
different topical formulations of diclofenac (48), as well as quantitative structure-permeation 315 
relationship (QSPR) models, porous models, transient models such as compartment models, 316 
and slow partition kinetic models, to describe transdermal drug delivery (49). Additionally, 317 
multiple pharmacokinetic dermal models for the simulation of drug permeation through the 318 
skin for topical applications have been developed (32). However, no intradermal models for 319 
the simulation of LA formulation administration using MAPs has yet been reported. 320 
The described intradermal PBPK model provides a valuable estimate of formulation require-321 
ments for MAP delivery but is characterised by several limitations. The dose and release rates 322 
were simulated in optimal conditions and do not include any loss of drug during application. 323 
This includes the assumption of 100% bioavailability during dose predictions and lower frac-324 
tion can increase the dose required thus increasing the size of the microneedle patch. A canon-325 
ical shaped needle has been simulated in this study; changes in the shape and size of the mi-326 
croneedle such as pyramidal or tetrahedral, or an increase in microneedle density could be used 327 
to tune the release rate and diffusion following application. Ethnicity and sex are additional 328 
patient factors that can influence pharmacokinetics following intradermal administration. How-329 
ever, their effect on release kinetics has not been evaluated in clinical studies to date. Lag time 330 
after the application of MAPs has not been considered in this model, and a delay could be 331 
observed in the Cmax and tmax as a consequence. The human dermis is highly vascularized, and 332 
vasodilation or vasoconstriction could lead to altered drug release from the depot, affecting 333 
plasma pharmacokinetics (50, 51). Highly lipophilic drugs and particles less than 100 nm tend 334 
 
to enter the lymphatic circulation rather than blood, which may impact pharmacokinetics (52). 335 
Drug transport proteins play a key role in defining the pharmacokinetic profile of many drugs, 336 
but limited data relating to this site of delivery restricted their inclusion in the PBPK model. 337 
Complexity in the design of nanoformulations with the estimated release rates from current 338 
technology used in this model could also prove to be a limiting factor.  339 
The qualified intradermal PBPK model has been cross-checked only against rat data for one 340 
drug, as this was the only relevant in vivo data in the published literature. Qualification against 341 
observed human data and diverse formulations will further improve confidence in the predic-342 
tive value of the model. Long-term stability and tolerability of drug formulation at the site of 343 
administration in human skin must be investigated thoroughly to prevent any unwanted side 344 
effects. Transdermal drug administration is attractive for neonatal and paediatric applications, 345 
but this model only investigated the kinetics of drug delivery in average sized adults.  346 
 
Conclusion  347 
PBPK models have been successfully qualified for oral and IM rilpivirine and cabotegravir. A 348 
novel intradermal model has been qualified against observed data in rats and nanoformulation 349 
design has been informed for MAP administration in humans. Optimal doses between ranges 350 
of release rates suitable for intradermal delivery, and preferred dosing intervals were simulated 351 
such that plasma concentrations remained above target trough concentrations throughout dos-352 
ing intervals. Based on our simulations, q4-weekly cabotegravir and q-weekly cabotegravir and 353 
rilpivirine MAPs are feasible with patch sizes less than 60 cm2, and q-monthly rilpivirine would 354 
be possible with a denser MAP. This model could provide a useful platform to inform the 355 
design of novel formulations for chronic transdermal drug administration. 356 
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Tables 531 
Table 1. Physicochemical properties, in vitro and population pharmacokinetic data of anti-532 
HIV drugs 533 
 
Rilpivirine (rat) Rilpivirine (human) Cabotegravir (human) 
log Po:w 4.32 (53) 4.32 (53) 2.2 (23) 
Protein binding 99.7% (53) 99.7% (53) 99.3% (23) 
pKa 3.26 (53) 3.26 (53) 4.14 (23) 
Blood-to-plasma ratio 0.67 (53) 0.67 (53) 0.441 (23) 
Plasma clearance 1.3 L/kg/h †2.04 (53) 
†4.5 (1A1) / 2.2 (1A9) 
(23) 
IM release rate (h-1) 2.6 × 10-2   *9 × 10-4   4.54 × 10-4 (23)    
Intradermal release rate 
(h-1) ‡2 × 10-4   - 
- 
Dose 5, 20 mg/kg IM, 120 mg TD - - 
Values are presented as mean (reference). log Po:w – Partition coefficient between octanol and water; pKa – loga-534 
rithmic value of the dissociation constant;  ‡Release rate followed a linear increase with respect to time shown in 535 
the following equation: (0.005/1344)*time+0.0002, time in hours. †Values represent intrinsic clearance in 536 
µl/min/pmol, rilpivirine is metabolised by CYP3A4, and cabotegravir by UGT1A1 and UGT1A9. * Release rate 537 
observed for an old formulation of rilpivirine derived using the PBPK model (38).  538 
 
Table 2. Validation of the PBPK model for IM (38) and intradermal rilpivirine formulations in 539 
rats in vivo 540 
 541  
Observed Simulated (n =100) 
% difference  
simulated vs. clinical 
Route of ad-
ministration 
and dose 
Cmax 
AUC0-
56 days 
Ctrough Cmax AUC0-last Ctrough Cmax 
AUC0-
56 days 
Ctrough 
Intramuscular 
(5 mg/kg, single 
injection) 
71 3840 - 55.9 ± 6.43 5.67 ± 1.25 - -21.3 47.6 - 
Intramuscular 
(20 mg/kg, sin-
gle injection) 
158 15300 - 222 ± 25.5 22.4 ± 4.64 - 40.5 46.3 - 
Intradermal 
† (120 mg, mi-
croneedle patch) 
416 - 26.5 481 ± 42.9 286 ± 28.1 38.7 ± 4.45 24.5 - 
46.0 
Values are represented as arithmetic mean ± standard deviation wherever applicable; AUC0-last – area under the 542 
concentration-time curve, Cmax – maximum plasma concentration, Ctrough – trough plasma concentration; Cmax and 543 
Ctrough are expressed as ng/ml and AUC is expressed as µg × h/ml; * PBPK model is assumed to be qualified if % 544 
difference is less than 50.† Only 57.45 % of the total administered drug was assumed to be delivered using mi-545 
croneedles (27).  546 
 
Figures 547 
 548 
 549 
Figure 1. Drug release pathway from the microneedles in the intradermal compartment reach-550 
ing the blood and lymphatic circulation. AHF, ASC, AVE  – drug amount penetrating the hair 551 
follicles, stratum corneum and viable epidermis respectively; DDE, DSC, DVE – microneedle 552 
drug depot in the dermis, stratum corneum and viable epidermis respectively; DSCD, DVED – 553 
amount of released drug from the nanoparticles in the stratum corneum and viable epidermis 554 
respectively; Ks, KSC, KVE – rate of drug permeation from microneedle to skin, microneedle to 555 
stratum corneum and microneedle to viable epidermis respectively; KTD – drug release rate 556 
from the encapsulated nanoparticles; PCSC/VE, PCS/W – drug partition coefficient between stra-557 
tum corneum & viable epidermis and skin & water respectively.  558 
 
 559 
Figure 2. Representative drug deposition subsequent to microneedle insertion in different lay-560 
ers of the skin at time t = 0 h for varying insertion depths. L - microneedle insertion depth, r – 561 
radius of the created pore; DSC, DVE, DDE – amount of drug present in stratum corneum, viable 562 
epidermis and dermis respectively.563 
 
 564 
Figure 3. Ctrough values of cabotegravir (a, b) and rilpivirine (c, d) – 4-weekly loading (a, c) and maintenance (b, d) doses for various release rates. 565 
The red lines represent the target concentrations considered for this dose optimisation study. LD – loading dose, PO – once daily. Error bars 566 
represent the standard deviation.567 
 
 568 
 569 
Figure 4. Ctrough values of cabotegravir (a, b) and rilpivirine (c, d) – weekly loading (a, c) and maintenance (b, d) doses for various release rates. 570 
The red lines represent the target concentrations considered for this dose optimisation study. LD – loading dose. Error bars represent the standard 571 
deviation.572 
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 574 
 575 
Figure 5. Pharmacokinetic parameters AUC, Cmax and Ctrough of rilpivirine for various (a) pen-576 
etration depths and (b) microneedle pore radius. Error bars represent the standard deviation.  577 
(a) 
(b) 
 
 578 
Figure 6. Effect on plasma concentration of rilpivirine at (a) various release rates in h-1 at a 579 
constant dose of 720 mg and (b) varying doses at a constant release rate of 1.5x10-3 h-1. 580 
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